Supplementation With Sirtuin Activators in Women With Increased Body Weight
NCT ID: NCT07245979
Last Updated: 2025-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2025-10-08
2027-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does sirtuin activators affect lipid and carbohydrate metabolism? Does sirtuin activators affect oxydative stress, immune functions and cell ageing?
Researchers will compare sirtuin activators to a placebo (a look-alike substance that contains no drug) to see if drug sirtuin activators works to improve metabolic status.
Participants will:
Take sirtuin activators or a placebo every day for 6 months. Visit the university once every 3 months for checkups and tests.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TAC, SOD and MDA Responses to Aerobic Exercise Versus Phoenix Seed in Obese Sedentary Females
NCT07073716
Effect of Exercise and Omega-3 on Metabolic Health in Elderly
NCT03386461
Evaluation of Sinetrol® Xpur in Fat Mass Reduction on Overweight and Obese Subjects
NCT04149158
Sirtuin Mediated Effects of 36 Hour Fast and 1 Hour Exercise
NCT00978640
Supplement and Exercise Effects on Stationary Immunity and Health in Older Adults
NCT07251244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: sirtuin activators
Sirtuin activators supplementation for 6 months, daily dose of 1278 mg, taken twice a day in a capsulated form. One capsule will contain: resveratrol - 500 g, leucin - 467 mg, Epigallocatechin gallate - 100 mg, quercetin - 100 mg, curcuminoids - 100 mg, niacin 10.7 g. Daily number of capsules will be 2 x 2 = 4.
Sirtuin activators
Sirtuin acitivators supplementation for 6 months
Placebo comparator: placebo
Placebo will be an inactive substance (maltodextrin) provided in the same-looking capsules as sirtuin activators. Placebo will be administered twice a day, daily number of capsules will be 2 x 2 = 4.
Placebo
Placebo supplementation for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sirtuin activators
Sirtuin acitivators supplementation for 6 months
Placebo
Placebo supplementation for 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age: 40-65 years
* overweight or obese: BMI \>25 kg/m2
Exclusion Criteria
* BMI \< 25 kg/m2
* sirtuin activators administration for 3 months prior to study
* pregnancy or breastfeeding
* recent dieting or being on calorie restricted diet
* receiving pharmacotherapy to treat obesity, diabetes or hyperlipidemia
* post-bariatric surgery
* diabetes
* cancer
* chronic kidney, liver or autoimmune diseases
* alcohol addiction
40 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poznan University of Medical Sciences
OTHER
Nutropharma sp. z o.o.
UNKNOWN
Poznan University of Life Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Agata Chmurzyńska
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Agata Chmurzynska, Professor
Role: PRINCIPAL_INVESTIGATOR
Poznan Univeristy of Life Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poznan University of Life Sciences
Poznan, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sirt activators
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.